Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CN-201 in Rheumatoid Arthritis: NCT07363590 Clinical Landscape Report 2026
18 September 2026
NCT07363590 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab tirumotecan in Triple Negative Breast Cancer: NCT07371208 Clinical Landscape Report 2026
18 September 2026
NCT07371208 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atropine Sulfate in Advanced Triple-Negative Breast Carcinoma: NCT07367178 Clinical Landscape Report 2026
18 September 2026
NCT07367178 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Temozolomide in Glioblastoma: NCT07365280 Clinical Landscape Report 2026
18 September 2026
NCT07365280 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Mismatch repair-deficient Endometrial Carcinoma: NCT07369986 Clinical Landscape Report 2026
18 September 2026
NCT07369986 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Everolimus in Hepatocellular Carcinoma: NCT07369505 Clinical Landscape Report 2026
18 September 2026
NCT07369505 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Triple Negative Breast Cancer: NCT07372079 Clinical Landscape Report 2026
18 September 2026
NCT07372079 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oliceridine fumarate in Anesthesia: NCT07372209 Clinical Landscape Report 2026
18 September 2026
NCT07372209 clinical landscape for Anesthesia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CMG1A46 in Sjogren's Syndrome: NCT07371468 Clinical Landscape Report 2026
18 September 2026
NCT07371468 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Benmelstobart in Endometrial Carcinoma: NCT07371663 Clinical Landscape Report 2026
18 September 2026
NCT07371663 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enzalutamide in Breast Cancer: CTRI/2026/01/102272 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/01/102272 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07376629 Clinical Landscape Report 2026
18 September 2026
NCT07376629 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.